Benefit of cetuximab addition to a platinum–fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers

Vianney Bastit (1) , Nicolas Bon-Mardion , Jean-Michel Picquenot (2) , Vinciane Rainville (2) , Cristian Moldovan , Arnaud François (3, 4) , Agnès Loeb , Sebastien Thureau (5) , Dorel Manu , Fabrice Jardin (2) , Jean-Paul Marie , Frédéric Di Fiore , Florian Clatot (2)

1 UNIROUEN UFR Santé - UNIROUEN - UFR Santé
2 GPMCND - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques
3 ERRAPHIS - Equipe de Recherche sur les Rationalités Philosophiques et les Savoirs
4 ESCAPE - Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle
5 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle

Domains: Life Sciences [q-bio]; Life Sciences [q-bio]; Human health and pathology; Life Sciences [q-bio]; Cancer

Vianney Bastit, Nicolas Bon-Mardion, Jean-Michel Picquenot, Vinciane Rainville, Cristian Moldovan, et al.. Benefit of cetuximab addition to a platinum–fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers. European Archives of Oto-Rhino-Laryngology, 2019, 276 (2), pp.541-550. ⟨10.1007/s00405-018-5235-6⟩. ⟨hal-02316581⟩